Agilent Technologies, Inc. v. Axion Biosystems, Inc.

Summary

The United States District Court for the District of Delaware granted Axion Biosystems, Inc.’s motion for summary judgment on Agilent Technologies, Inc.’s false advertising claim under Section 43(a) of the Lanham Act. The court held that Agilent lacked sufficient evidence of actual customer deception and injury proximately caused by Axion’s advertising statements. The court denied Axion’s separate damages motion as moot.

Holdings

1. A plaintiff seeking monetary relief for a Lanham Act false-advertising claim must present proof of actual consumer deception, even if the alleged statements are literally false. Agilent's inadmissible double-hearsay, vague testimony, and evidence concerning sophisticated researchers did not create a genuine dispute of material fact as to actual deception.
2. Agilent failed to present sufficient evidence of economic or reputational injury proximately caused by the Maestro Statements, and therefore could not establish the injury element of its false-advertising claim.
3. Agilent could not recover prospective corrective-advertising costs because it failed to present sufficient evidence of the underlying deception and injury that corrective advertising would remedy.

Questions Presented

1. Whether Agilent presented sufficient evidence to create a genuine dispute of material fact regarding actual deception or a tendency to deceive under the Lanham Act.
2. Whether Agilent presented sufficient evidence of injury proximately caused by Axion's allegedly false or misleading advertising.
3. Whether Agilent could pursue prospective corrective-advertising costs when it lacked sufficient evidence of deception and injury.

Disposition

other